Special topical pharmaceuticals company, Transdel Pharmaceuticals, Inc., announced today that it has appointed industry veteran Terry Nida as its Chief Business Officer. With over 30 years of pharmaceutical industry experience, Mr. Nida has an impressive track record in negotiating and closing global and regional joint development, licensing, distribution, sales and marketing partnerships and supply agreements with numerous pharmaceutical companies.
Prior to joining Transel, Mr. Nida worked as an Executive Consultant for pharmaceutical and biotechnology companies. He held positions as Chief Operating Officer at Urigen Pharmaceuticals from 2006 to 2008 and Vice President Corporate Development, Marketing and Sales at VIVUS from 1995 to 2006. He also held senior management positions with Carrington Laboratories, Centocor and began his career at Bristol Myers.
The Board of Directors of Transdel Pharmaceuticals is extremely pleased to welcome Terry to the company to drive its business and corporate development strategies. Mr. Nida’s addition to the team is an important step towards promoting its lead topical pain product, Ketotransdel®.
Mr. Nida commented, “I believe that Ketotransdel is an excellent product that presents substantial commercial opportunity. Also, the company’s Transdel™ transdermal drug delivery platform technology has significant potential for development of additional products identified by the company for the pharmaceutical, cosmeceutical and dermatological markets. I look forward to forming collaborations with potential partners to bring these products to market.”